Astellas Pharma Inc — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications3liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
FK962The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.	Alzheimer	Phase 2	À vérifier	United States, Canada	À vérifier
FK962The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.	Alzheimer	Phase 2	À vérifier	United States, Canada	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
FK962	Alzheimer	Phase 2	NCT00087724	A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease	TERMINATED

Publications

3

Molécule	Indication / population	Titre	Journal	Date
FK962		FK962 induces neurite outgrowth in cultured monkey trigeminal ganglion cells.	Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
FK962		In Silico Ocular Pharmacokinetic Modeling: Delivery of Topical FK962 to Retina.	Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
FK962		FK962 protects retinal ganglion cell under hypoxia/reoxygenation: Possible involvement of glial cell line-derived neurotrophic factor signaling pathway.	Experimental eye research